TY - JOUR
T1 - Hormones and Cardiovascular Disease: A Shift in Paradigm with Clinical Consequences?
AU - van Zaane, Bregje
AU - Reuwer, Anne Q.
AU - Büller, Harry R.
AU - Kastelein, John J. P.
AU - Gerdes, Victor E. A.
AU - Twickler, Marcel Th B.
PY - 2009
Y1 - 2009
N2 - Several endocrine disorders have been associated with an increased risk of cardiovascular disease (CVD) and mortality. In addition, even subtle hormonal disturbances may modulate the function of cardiovascular organs. In this article, we discuss in detail the contribution of thyroid hormones, cortisol, the somatotropic hormones, and prolactin in the development of CVD. We do not only discuss epidemiological evidence on the association between hormones and cardiovascular disease, but we also address possible pathophysiological mechanisms underlying this association. In fact, hormones can contribute to the development of CVD both indirectly by inducing secondary metabolic changes such as hypertension, insulin resistance, or dyslipidemia, and directly by modulation of cellular pathways that are important in the process of atherosclerotic plaque formation (atherogenesis), plaque instability, and thrombosis. To date several new therapeutic approaches that focus on the control of hormones at the tissue level, independently of their circulating levels, are being developed. These may offer new possibilities for cardiovascular risk reduction
AB - Several endocrine disorders have been associated with an increased risk of cardiovascular disease (CVD) and mortality. In addition, even subtle hormonal disturbances may modulate the function of cardiovascular organs. In this article, we discuss in detail the contribution of thyroid hormones, cortisol, the somatotropic hormones, and prolactin in the development of CVD. We do not only discuss epidemiological evidence on the association between hormones and cardiovascular disease, but we also address possible pathophysiological mechanisms underlying this association. In fact, hormones can contribute to the development of CVD both indirectly by inducing secondary metabolic changes such as hypertension, insulin resistance, or dyslipidemia, and directly by modulation of cellular pathways that are important in the process of atherosclerotic plaque formation (atherogenesis), plaque instability, and thrombosis. To date several new therapeutic approaches that focus on the control of hormones at the tissue level, independently of their circulating levels, are being developed. These may offer new possibilities for cardiovascular risk reduction
U2 - https://doi.org/10.1055/s-0029-1234143
DO - https://doi.org/10.1055/s-0029-1234143
M3 - Article
C2 - 19739038
SN - 0094-6176
VL - 35
SP - 478
EP - 487
JO - Seminars in thrombosis and hemostasis
JF - Seminars in thrombosis and hemostasis
IS - 5
ER -